Five people with Alzheimer's disease kept using a simple device in their homes for two years: an LED panel and speaker that pulsed light and sound at 40 hertz, a frequency that MIT researchers believe can strengthen brain waves and protect neurons. For three of them—all women with late-onset Alzheimer's—the results were striking enough to suggest the therapy actually works.
Their cognitive scores stayed significantly higher than what national databases predict for Alzheimer's patients at the same disease stage. More tellingly, when researchers tested their blood, they found phosphorylated tau—a protein that accumulates in Alzheimer's brains and damages them—had dropped by 19 to 47 percent. This matters because tau reduction is one of the few measurable signs that Alzheimer's progression might actually be slowing.
"One of the most compelling findings was the significant reduction of plasma pTau217, a biomarker strongly correlated with Alzheimer's pathology," the study authors wrote in Alzheimer's & Dementia. "These results suggest GENUS could have direct biological impacts on Alzheimer's pathology."
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxHow a Tiny Trial Led to Real Questions
The story started in 2020 when MIT enrolled 15 people with mild Alzheimer's disease in an early trial. The setup was deliberately unglamorous—an hour each day of flickering light and humming sound at 40 hertz, delivered through devices people could use at home. Earlier research in mice had shown this frequency could increase certain brain waves, preserve neurons, and reduce amyloid and tau buildup. But mice aren't people, and early trials often don't translate.
The initial three-month results were promising enough that five participants chose to keep going when the formal study ended. Two years later, three of those five showed sustained benefits.
But there's a complication. The two male participants with early-onset Alzheimer's—a more aggressive form that strikes people in their 50s and 60s—showed no cognitive benefit and their brains actually became less responsive to the stimulation over time. The researchers don't think gender is the issue; they suspect early-onset Alzheimer's involves different biological pathways that this therapy doesn't address.
"GENUS may be less effective in early-onset Alzheimer's disease patients, potentially owing to broad pathological differences," the team noted, adding that future research needs to identify who will actually benefit before offering the therapy widely.
What Comes Next
This is still a very small study—five people continuing a therapy is not proof it works broadly. But it's evidence worth pursuing. The tau reductions in particular suggest something real is happening at the cellular level, not just mood improvement or placebo effect. MIT is now recruiting people aged 55 and older with normal memory but a family history of Alzheimer's to see if the therapy might prevent the disease entirely, rather than just slowing it once it starts. That's the kind of preventative approach that could matter for millions.
